Currently under build to become FDF manufacturing site
Acquired in 2015, the site will significantly strengthen Xellia’s manufacturing capacity for sterile injectable products. We expect to commence the final FDA approval process in 2019 following which we will be able to commence full manufacturing operations at the site.
Our Cleveland production site will operate alongside Xellia’s other existing production facilities and produce sterile injectable products. The site includes four manufacturing units for sterile injectables and has currently more than 180 employees across a range of departments, including; manufacturing, supply chain, distribution, quality, engineering, human resources and finance.